Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (86)	6/11/2001 10:08:16 AM
From: tuck	Read Replies (1) \| Respond to of 1005

While MCLS & AGNT continue to defy the slow rollover of the market, CURN also has news today on its second product in development: >>SUNNYVALE, Calif., June 11 /PRNewswire/ -- Curon Medical, Inc. (Nasdaq: CURN - news) today commented on the presentation of positive one-year follow-up results from the Company's Secca System Pilot Trial. Dr. Takeshi Takahashi, the study's principal investigator, reported the data at the annual meeting of the American Society of Colon and Rectal Surgeons held in San Diego, California, on Tuesday, June 5, 2001. The pilot study was conducted to investigate the feasibility, safety, and efficacy of the Secca System for the treatment of fecal incontinence. The study included ten patients with fecal incontinence of varying causes, all of whom had failed other therapies and were experiencing devastating reductions in quality of life due to this disorder. Dr. Takahashi communicated that the procedure, which was performed using local anesthesia on an outpatient basis, was well tolerated by all patients. Eight out of ten patients (80%) experienced significant symptomatic improvement, defined as 50% or greater reduction in incontinence severity, as well as statistically significant improvement in all four components of the Fecal Incontinence Quality of Life Survey. ``There was continued symptom improvement as patients approached the one-year follow-up interval, suggesting promise for durability,'' stated Dr. Takahashi. ``There is a largely unmet medical need for a procedure to effectively treat fecal incontinence,'' said, John W. Morgan, President and Chief Executive Officer of Curon Medical. ``This disorder affects up to 16 million adults in the United States. Fecal incontinence has a major impact on the quality of life for patients, and unfortunately is often left untreated due to embarrassment on the part of the patient and lack of treatment options available to physicians. We are optimistic that our U.S. trial will continue to demonstrate the safety and efficacy of the Secca procedure as initially seen in this pilot study, and that soon this procedure will be available to provide relief to those suffering from fecal incontinence.'' In addition, Curon Medical recently completed the treatment phase of the Secca System IDE clinical trial. Fifty patients were treated at five U.S. sites including Cleveland Clinic, Ft. Lauderdale; Washington University, St Louis; University of Southern California; Graduate Hospital, Philadelphia; and University of Michigan. Submission of the results of this trial to the U.S. Food and Drug Administration is expected in the fourth quarter of 2001. About Curon Medical Curon Medical, Inc. develops, manufactures and markets innovative proprietary products for the treatment of gastrointestinal disorders. The Company's products consist of radiofrequency generators and single use disposable devices. Its first product, The Stretta® System, received U.S. Food and Drug Administration clearance in April 2000 for the treatment of gastroesophageal reflux disease, commonly referred to as GERD. For more information, please visit the Company's website at curonmedical.com.<< snip Cheers, Tuck